LRFN5 and OLFM4 in Bipolar Disorder

This cross-sectional observational case-control study evaluated serum levels of leucine-rich repeat and fibronectin type III domain-containing protein 5 (LRFN5) and olfactomedin-4 (OLFM4) in subjects with bipolar disorder (BD) during acute manic episodes and in healthy controls (HC). The study also assessed systemic inflammation using the Aggregate Index of Systemic Inflammation (AISI) and examined associations between biomarkers and clinical symptom severity, including Young Mania Rating Scale (YMRS) and Beck Depression Inventory (BDI) scores. The study aimed to investigate the potential interaction between synaptic dysregulation and immunoinflammatory abnormalities in BD.

NCT Number	NCT07434414
Lead Sponsor	Elazığ Mental Health and Diseases Hospital
Conditions	Bipolar Disorder (BD)
Enrollment	72 participants
Start Date	2025-07-07
Primary Completion	2026-01-02 (estimated)
Study Completion	2026-01-02 (estimated)
Updated on ClinicalTrials.gov	2026-06-29